Exelixis’ Cabometyx approved in second-line liver cancer in USExelixis’ cancer drug Cabometyx has been approved in a new liver cancer use in the US, providing a Share XExelixis’ Cabometyx approved in second-line liver cancer in UShttps://pharmaphorum.com/news/exelixis-cabometyx-approved-in-second-line-liver-cancer-in-us/
Ipsen warns over medicine supplies amid Brexit uncertaintyFrance’s Ipsen has become the latest pharma company to warn about the impact of Brexit on the pharma Share XIpsen warns over medicine supplies amid Brexit uncertaintyhttps://pharmaphorum.com/news/ipsen-warns-over-medicine-supplies-amid-brexit-uncertainty/
AZ begins liver cancer immunotherapy tie-up with AVEOAstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in Share XAZ begins liver cancer immunotherapy tie-up with AVEOhttps://pharmaphorum.com/news/az-begins-liver-cancer-immunotherapy-tie-up-with-aveo/
Merck gets FDA okay for Keytruda as liver cancer therapyMerck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular Share XMerck gets FDA okay for Keytruda as liver cancer therapyhttps://pharmaphorum.com/news/merck-gets-fda-okay-for-keytruda-as-liver-cancer-therapy/
EU regulators back Ipsen cancer drug in new liver cancer useIpsen’s bid to build a cancer franchise around its Cabometyx (cabozantinib) is gathering pace after European regulators backed Share XEU regulators back Ipsen cancer drug in new liver cancer usehttps://pharmaphorum.com/news/eu-regulators-cabometyx-liver/
Eisai/Merck & Co’s Lenvima approved in EU for first line liver cancerThe European Commission has approved Eisai/Merck & Co’s Lenvima as a new first-line treatment for liver cancer. Eisai Share XEisai/Merck & Co’s Lenvima approved in EU for first line liver cancerhttps://pharmaphorum.com/news/eisai-merck-cos-lenvima-approved-in-eu-for-first-line-liver-cancer/
Raising the bar in liver cancer therapypharmaphorum interviews professor Jeff Evans, from the University of Glasgow’s Institute of Cancer Sciences, about findings of a Share XRaising the bar in liver cancer therapyhttps://pharmaphorum.com/oncology/insights-oncology/raising-bar-liver-cancer-therapy/
Eisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s successGary Hendler, chairman and CEO of EMEA region for Eisai, talked to Richard Staines at pharmaphorum about findings Share XEisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s successhttps://pharmaphorum.com/oncology/insights-oncology/eisais-emea-ceo-gary-hendler-lenvimas-success/
Ipsen aims for new liver cancer use of CabometyxStopping a cancer trial is either a very good, or very bad thing – and luckily for Ipsen Share XIpsen aims for new liver cancer use of Cabometyxhttps://pharmaphorum.com/news/ipsen-aims-new-liver-cancer-use-cabometyx/
